Examkin

Question

Difficulty: Very hardPsychopharmacology and Psychological Therapies

A 34-year-old male with a history of treatment-resistant schizophrenia is hospitalized for the management of severe lower extremity cellulitis. His daily psychiatric regimen includes clozapine 400 mg daily, which has successfully managed his psychotic symptoms for the past two years without major adverse effects. The patient has a 15-pack-year smoking history and typically smokes two packs of cigarettes daily. Because the hospital is a strict tobacco-free facility, he is prescribed a continuous 21-mg nicotine transdermal patch upon admission to prevent withdrawal. On hospital day 4, the nursing staff notes that the patient is profoundly sedated, confused, and experiencing excessive drooling. Later that afternoon, he suffers a witnessed generalized tonic-clonic seizure. Vital signs reveal a blood pressure of 100/60 mmHg and a heart rate of 112/min. Laboratory studies show a leukocyte count of 7,500/mm³ and a normal basic metabolic panel. Which of the following pharmacological mechanisms is the most likely primary cause of this patient's acute neurological complication?

  1. Loss of cytochrome P450 enzyme inductionAnswer
  2. B
    Inhibition of uridine 5'-diphospho-glucuronosyltransferase
  3. C
    Pharmacodynamic synergism at central serotonergic receptors
  4. D
    Decreased renal tubular excretion of the maintenance medication
  5. E
    Downregulation of central gamma-aminobutyric acid receptors

Answer

The most likely cause of the patient's acute presentation is the loss of cytochrome P450 enzyme induction due to smoking cessation.
The patient's presentation of a new-onset generalized tonic-clonic seizure, profound sedation, sialorrhea (excessive drooling), and hypotension is highly characteristic of acute clozapine toxicity. Clozapine is an atypical antipsychotic that is extensively metabolized by the hepatic enzyme cytochrome P450 1A2 (CYP1A2). Tobacco smoke contains polycyclic aromatic hydrocarbons (PAHs), which are potent inducers of CYP1A2. When a heavy smoker is admitted to a smoke-free hospital, the abrupt cessation of PAH exposure leads to a rapid loss of CYP1A2 induction. Consequently, the previously established home dose of clozapine is no longer metabolized at the same accelerated rate, causing its serum concentration to spike dramatically. High serum levels of clozapine are directly associated with dose-dependent toxicities, including a significantly increased risk of seizures. Importantly, while nicotine replacement therapy (such as the transdermal patch) effectively treats nicotine withdrawal cravings, it does not contain the PAHs found in combustible tobacco, meaning it cannot maintain the crucial CYP1A2 induction.

Step-by-Step Solution

1
Analyze the patient's acute clinical presentation.
The patient developed new-onset generalized tonic-clonic seizures, profound sedation, sialorrhea (drooling), hypotension, and tachycardia.
Identifying the clinical syndrome is essential for recognizing it as acute clozapine toxicity, which has a known dose-dependent risk of seizures.
2
Review the patient's medication and environmental changes upon hospitalization.
The patient was maintained on clozapine but transitioned from heavy cigarette smoking (2 packs per day) to a nicotine transdermal patch.
Environmental and therapeutic shifts during transitions of care often trigger adverse pharmacological events.
3
Recall the pharmacokinetic relationship between smoking, clozapine, and the prescribed alternative.
Polycyclic aromatic hydrocarbons (PAHs) in tobacco smoke strongly induce CYP1A2. Nicotine replacement therapy provides nicotine but lacks PAHs, failing to maintain this induction.
Understanding the specific metabolic pathway differentiates the effects of the actual tobacco smoke from the chemical effects of nicotine.
4
Synthesize the mechanism to explain the outcome.
Abrupt cessation of PAHs leads to a rapid loss of CYP1A2 induction. The standard home dose of clozapine (a major CYP1A2 substrate) is no longer rapidly metabolized, causing serum levels to spike into the toxic range and trigger dose-dependent seizures.
This confirms that the loss of induction is the primary mechanism driving the patient's neurological complication.

Key Concept

Polycyclic aromatic hydrocarbons in tobacco smoke strongly induce cytochrome P450 1A2 (CYP1A2). Abrupt smoking cessation in a patient on a stable dose of a CYP1A2 substrate (like clozapine) causes a rapid loss of induction, leading to toxic serum drug levels. Nicotine patches do not contain hydrocarbons and will not prevent this interaction.
Rate this question

Topics

Psychopharmacology and Psychological Therapies

More questions from this topic